Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
NCT ID: NCT00536692
Last Updated: 2008-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2007-09-30
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Describing Patient With DME, Their Patient Journey and Disease Progression
NCT05966753
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
NCT00457470
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
NCT00320814
Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema
NCT05343156
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
NCT03511898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mecamylamine
topical ocular drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* intraocular surgery within 3 months
* intraocular anti-VEGF or steroids within 3 months
* HbA1c \>12
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juvenile Diabetes Research Foundation
OTHER
CoMentis
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Bay Retina Consultants, Inc.
Oakland, California, United States
Johns Hopkins School of Medicine / Wilmer Eye Institute
Baltimore, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Campochiaro PA, Shah SM, Hafiz G, Heier JS, Lit ES, Zimmer-Galler I, Channa R, Nguyen QD, Syed B, Do DV, Lu L, Monk J, Cooke JP, Kengatharan MK, Hsu HH. Topical mecamylamine for diabetic macular edema. Am J Ophthalmol. 2010 May;149(5):839-51.e1. doi: 10.1016/j.ajo.2009.12.005. Epub 2010 Feb 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATG003-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.